Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic.
Saved in:
| Title: | Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic. |
|---|---|
| Authors: | Kimura, Sakiko1 (AUTHOR) mochinag@cc.saga-u.ac.jp, Katsuya, Hiroo2 (AUTHOR), Nakashima, Chiho2 (AUTHOR), Sueoka-Aragane, Naoko2 (AUTHOR), Hayashida, Koji3 (AUTHOR), Sasaki, Kazumi4 (AUTHOR), Sogawa, Rintaro1 (AUTHOR), Furuno, Tatsuya1 (AUTHOR), Yamauchi, Moriyasu5 (AUTHOR), Sugiyama, Yoichiro5 (AUTHOR), Noshiro, Hirokazu6 (AUTHOR), Esaki, Motohiro7 (AUTHOR), Noguchi, Mitsuru8 (AUTHOR), Takahashi, Hirokazu9 (AUTHOR), Anzai, Keizo10 (AUTHOR), Yokoyama, Masatoshi11 (AUTHOR), Sugita, Kazunari12 (AUTHOR), Yamashita, Yoshio13 (AUTHOR), Kawaguchi, Atsushi14 (AUTHOR), Kimura, Shinya2 (AUTHOR) |
| Source: | BMC Immunology. 4/16/2025, Vol. 26 Issue 1, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
